The Selective Cox-2 Inhibitor Etoricoxib Reduces Acute Inflammatory Markers in a Model of Neurogenic Laryngitis but Loses Its Efficacy with Prolonged Treatment
AuthID
P-003-3EA
P-003-3EA
© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service